indication
as of 2026-07-01Autistic Disorder
Competitive landscape projected to Risperidone’s launch window
Competitive set
2
2 approved · 0 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
21 events
2018
2020
2022
2024
2026
2028
2030
2032
today
Risperidone launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugfocal
US-approved 1993 · RISPERDAL
Phase 41 trial
Protection2042
drugCompleted
US-approved 2010 · Latuda
Phase 33 trials
Protection2031
Market size
prevalence as a range, not a number